公式財務諸表に基づく売上高、利益、キャッシュフローの推移。
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→
| 損益計算書 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 売上高合計 | $2.8B | $2.5B | $2.1B | $1.9B | $1.5B | $1.1B | $926M | $861M | $705M | $436M | $422M | $359M | $290M | $273M |
| 売上総利益 | $800M | $761M | $656M | $525M | $432M | $328M | $279M | $246M | $216M | $175M | $172M | $156M | $134M | $124M |
| 売上総利益率 % | 28.8% | 30.1% | 31.1% | 27.8% | 29.6% | 28.7% | 30.1% | 28.5% | 30.6% | 40.1% | 40.8% | 43.6% | 46.1% | 45.6% |
| 営業利益（EBIT） | $583M | $535M | $447M | $337M | $279M | $199M | $167M | $127M | $101M | $65M | $52M | $21M | $26M | $59M |
| 営業利益率 % | 21.0% | 21.1% | 21.2% | 17.9% | 19.1% | 17.4% | 18.0% | 14.8% | 14.3% | 14.9% | 12.4% | 5.7% | 9.0% | 21.6% |
| 当期純利益 | $492M | $451M | $404M | $283M | $245M | $182M | $145M | $100M | $73M | $39M | $13M | ($9M) | ($16M) | $25M |
| 純利益率 % | 17.7% | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% | 15.7% | 11.7% | 10.4% | 9.0% | 3.2% | -2.4% | -5.4% | 9.1% |
| EBITDA | $613M | $571M | $505M | $362M | $308M | $223M | $187M | $150M | $140M | $111M | $99M | $89M | $94M | $88M |
| 1株当たり利益（EPS） | $16.90 | $15.28 | $12.63 | $8.88 | $7.29 | $4.82 | $3.86 | $2.67 | $1.98 | $0.98 | $0.37 | $-0.22 | $-0.53 | $0.65 |
| 発行済株式数（百万株） | 29M | 30M | 32M | 32M | 34M | 38M | 38M | 38M | 37M | 40M | 36M | 40M | 29M | 38M |
出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。
貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は MEDP のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/MEDP
本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。
About TickerBase · Data methodology & sources · Privacy · Terms